Indivior (NASDAQ:INDV) Price Target Cut to $13.00 by Analysts at Piper Sandler

Indivior (NASDAQ:INDV) had its target price decreased by Piper Sandler from $16.00 to $13.00 in a report published on Thursday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Several other analysts have also recently weighed in on INDV. Rodman & Renshaw started coverage on shares of Indivior in a research report on Tuesday, January 28th. They set a “buy” rating and a $16.00 price objective on the stock. RODMAN&RENSHAW upgraded shares of Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th.

Indivior Stock Performance

Indivior stock opened at $9.89 on Thursday. The firm’s fifty day moving average price is $10.97 and its 200-day moving average price is $10.62. The stock has a market cap of $1.36 billion, a P/E ratio of -28.26 and a beta of 0.73. Indivior has a fifty-two week low of $7.33 and a fifty-two week high of $22.53.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, February 20th. The company reported $0.32 earnings per share for the quarter, meeting the consensus estimate of $0.32. The firm had revenue of $298.00 million for the quarter, compared to analysts’ expectations of $262.35 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. On average, analysts predict that Indivior will post 1.22 earnings per share for the current year.

Hedge Funds Weigh In On Indivior

Large investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. purchased a new position in Indivior in the 4th quarter worth $36,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Indivior in the 4th quarter worth $56,000. Lazard Asset Management LLC bought a new stake in Indivior in the 4th quarter worth $57,000. Stifel Financial Corp bought a new stake in Indivior in the 3rd quarter worth $100,000. Finally, Melqart Asset Management UK Ltd bought a new stake in Indivior in the 3rd quarter worth $132,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.